Skip to main content

Day: May 24, 2023

Pyxis Oncology to Acquire Apexigen

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (“Pyxis Oncology”) (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, Inc. (Nasdaq:...

Continue reading

Navios Maritime Holdings Inc. Reports Financial Results for the First Quarter Ended March 31, 2023

Revenue$65.4 million in Q1 2023Net Income$14.5 million in Q1 2023EBITDA, a non-GAAP measure$40.5 million in Q1 2023Navios Logistics$26.0 million EBITDA, a non-GAAP measure, in Q1 2023GRAND CAYMAN, Cayman Islands, May 24, 2023 (GLOBE NEWSWIRE) — Navios Maritime Holdings Inc. (“Navios Holdings” or the “Company”) (NYSE: NM), today reported its financial results for the first quarter ended March 31, 2023. Navios Holdings owns (i) a controlling equity stake in Navios South American Logistics Inc. (“Navios Logistics”), one of the largest infrastructure and logistics companies in the Hidrovia region of South America and (ii) an interest in Navios Maritime Partners L.P. (“Navios Partners”) (NYSE:NMM), a United States publicly listed shipping company that owns and operates dry cargo and tanker vessels. Angeliki...

Continue reading

Dycom Industries, Inc. Announces Fiscal 2024 First Quarter Results

First Quarter HighlightsContract revenues of $1.045 billion; 19.3% growth Non-GAAP Adjusted EBITDA of $113.5 million, or 10.9% of contract revenue Net Income of $51.5 million, or $1.73 per common share diluted Repurchased 225,000 common shares for $20.3 million during the quarterPALM BEACH GARDENS, Fla., May 24, 2023 (GLOBE NEWSWIRE) — Dycom Industries, Inc. (NYSE: DY) announced today its results for the first quarter ended April 29, 2023. Contract revenues were $1.045 billion for the quarter ended April 29, 2023, compared to $876.3 million in the year ago period, an increase of 19.3%. Non-GAAP Adjusted EBITDA was $113.5 million, or 10.9% of contract revenues, for the quarter ended April 29, 2023, compared to $63.7 million, or 7.3% of contract revenues, in the year ago period. Net income was $51.5 million, or $1.73 per common...

Continue reading

Photronics Reports Second Quarter Fiscal 2023 Results

BROOKFIELD, Conn., May 24, 2023 (GLOBE NEWSWIRE) — Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its second quarter of fiscal year 2023 ended April 30, 2023. “We achieved record revenue in the second quarter with growth across IC and FPD as demand for our design-driven product remained high,” said Frank Lee, chief executive officer. “Mainstream IC demand remained robust across all regions, especially Asia and the US. FPD demand was driven primarily by AMOLED for advanced mobile displays as that technology continues to be adopted across new devices. Profit margins expanded on positive volume leverage, pricing, favorable mix, and tight control of cost. Cash generated from operating activities was very strong, enabling us to strengthen our balance sheet...

Continue reading

GigaCloud Technology Inc Announces First Quarter 2023 Financial Results, Reaching Highest Profitability in the Company’s History

HONG KONG, May 24, 2023 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce solutions for large parcel merchandise, today announced its unaudited financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial HighlightsTotal revenues were $127.8 million in the first quarter of 2023, an increase of 13.7% from $112.4 million in the first quarter of 2022. Gross profit was $29.6 million in the first quarter of 2023, an increase of 75.3% from $16.9 million in the first quarter of 2022. Gross margin increased to 23.1% in the first quarter of 2023, compared to 15.0% in the first quarter of 2022. Net income was $15.9 million in the first quarter of 2023, an increase of 236.4% from $4.7 million in the first quarter of 2022. Cash was...

Continue reading

The Vita Coco Company, Inc. Announces Upsizing and Pricing of Secondary Offering of Common Stock by Selling Stockholder

NEW YORK, May 24, 2023 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (Nasdaq: COCO) (“Vita Coco Company”), a leading high-growth platform of better-for-you beverage brands, today announced the upsizing and pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $23.00 per share, before deducting underwriting discounts and commissions, all of which are being sold by an existing stockholder, Verlinvest Beverages SA (the “Selling Stockholder”). The offering was upsized from the previously announced 4,500,000 shares of common stock. In addition, the Selling Stockholder has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. No shares of common stock are...

Continue reading

Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales. Life Edit has the option to a global profit share on one programme. Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing. Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – CT PROPERTY TRUST LTD – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – Londonmetric Property PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate...

Continue reading

trivago N.V. Announces Annual General Meeting of Shareholders

DÜSSELDORF, Germany, May 24, 2023 – trivago N.V. (NASDAQ: TRVG) announced today that its annual general meeting of shareholders will be held on June 30, 2023 at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. The meeting will start at 3:00 p.m. CEST. The convening notice and explanatory notes for the general meeting are available free of charge in the Investor Relations section of trivago N.V.’s corporate website at ir.trivago.com. About trivago N.V.trivago is a global hotel and accommodation search platform. We are focused on reshaping the way travelers search for and compare different types of accommodations, such as hotels, vacation rentals and apartments, while enabling our advertisers to grow their businesses by providing them with access to a broad audience of travelers via our...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.